Studying Genes in People With Heart Rhythm-Related Heart Muscle Disease
Observes genetic changes in adults with arrhythmia-induced cardiomyopathy and how they relate to outcome.
Plain-language title generated from the registry record
Registry title: Genetic Characterization of Patients With Arrhythmia-Induced Cardiomyopathy
Key facts
- Where
- Albacete, Ciudad Real, and Madrid, SpainSee the 4 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with atrial fibrillation or atrial flutter that does not stop on its own and a weakened heart pump (LVEF below 50%). It studies their genes and outlook.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Atrial fibrillation or atrial flutter that is not self-limited, with a heart scan showing LVEF <50%. The scan must be done within 3 months of the rhythm control procedure. If LVEF was already below 50% before, the drop caused by the fast rhythm must be ≥10%.
Main reasons for not taking part
- Earlier diagnosis of cardiomyopathy
- Severe mitral or aortic valve disease
- Heavy alcohol use (>80 grams of ethanol or >7 standard drinks per day)
- Active chemotherapy or radiation therapy to the chest
- Life expectancy under 1 year or no follow-up of at least 6 months possible
Read by machine on 9 November 2026.
Where in Spain
- Albacete University Hospital ComplexAlbacete, SpainNot yet recruiting
- Ciudad Real General University HospitalCiudad Real, SpainTaking people
- 12 de Octubre University HospitalMadrid, SpainTaking people
- Ramón y Cajal University HospitalMadrid, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Hospital Universitario 12 de Octubre
- Trial code
- NCT06896266
- Record updated
- 15 September 2026
- Original description
The goal of this observational study is to learn about the genetic insights of arrhythmya-induced cardiomyopathy and its clinical prognosis. The main questions it aims to answer are:Read full original descriptionShow less
Understanding and Characterizing the Genetics of Patients With Arrhythmia-Induced Cardiomyopathy
The goal of this observational study is to learn about the genetic insights of arrhythmya-induced cardiomyopathy and its clinical prognosis. The main questions it aims to answer are:
I. Does patients with arrhythmia-induced cardiomyopathy have a greater proportion of genetic mutations compared with other types of cardiomyopathy or general population? II. Have the genetics any prognostic impact in patients with arrhythmia-induced cardiomyopathy?
Inclusion: Presence of atrial fibrillation or atrial flutter not self-limited; Performance of a cardiac imaging test with systolic function analysis (echocardiogram, magnetic resonance, CT scan) during the clinical course of the arrhythmia, exhibiting a left ventricular ejection fraction (LVEF) <50%. In order for the test to be representative, the maximum time between the performance of the imaging test and the rhythm control procedure will be 3 months, in the absence of intervening cardiovascular events that may have caused a variation in LVEF. In the event that the patient had a previously known LVEF <50%, the change with respect to this attributable to tachyarrhythmia has to be ≥10%; Signature of informed consent; Ability to understand and accept participation in the study.
Exclusion: Presence of known factors causing systolic ventricular dysfunction:; Prior cardiomyopathy diagnosis; Severe mitral or aortic valve disease; Non-revascularizable ischemic heart disease; Context of peri-resuscitation cardiopulmonary care; Abusive alcohol consumption, defined as >80 grams of ethanol or >7 standard alcoholic beverages per day; Active treatment with chemotherapeutic agents or radiation therapy to the thorax; Known infection with Trypanosoma cruzi, Borrellia burgdorferi or other infectious agent causing cardiomyopathy; Age <18 years; Refusal of informed consent; Legal or juridical incapacity; Life expectancy less than 1 year; Impossibility of a follow-up of at least 6 months; Presence of a ventricular rate >140 beats per minute, limiting the validity of imaging measurements.